Interleukin-37 Serum Levels in Oral Squamous Cell Carcinoma

Ghaderi, Hamid; Fattahi, Mohammad Javad; Shirmardi Dezaki, Hossain; Malekzadeh, Mahyar; Khademi, Bijan; Ghaderi, Abbas; Haghshenas, Mohammad Reza

doi:10.30476/dentjods.2025.105421.2595

Interleukin-37 Serum Levels in Oral Squamous Cell Carcinoma

Document Type : Original Article

Authors

Hamid Ghaderi ¹

Mohammad Javad Fattahi ²

Hossain Shirmardi Dezaki ²

Mahyar Malekzadeh ²

Bijan Khademi ³

Abbas Ghaderi ²

Mohammad Reza Haghshenas ²

¹ Violet Vines Marshman Centre for Rural Health Research, La Trobe University, Bendigo, Australia.

² Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

³ Otolaryngology Research Center, Dept. of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.

https://doi.org/10.30476/dentjods.2025.105421.2595

Abstract

Background: Squamous cell carcinoma (SCC) is the most common cancer of the maxillofacial area, known for its high mortality and morbidity rates. Increasing evidence highlights the critical role of chronic inflammation in human malignancies by modulating inflammatory cells and cytokine synthesis. IL-37 is recognized as a cytokine that may play a dual role in cancer.
Purpose: This study sought to investigate IL-37 serum concentrations in individuals with oral SCC, specifically SCC of the tongue.
Materials and Method: This case-control study investigated IL-37 serum levels and their association with the patients' clinicopathological characteristics in 65 cases of oral SCC compared to 65 healthy controls using the ELISA technique. The study further assessed the diagnostic significance of IL-37 serum concentrations using receiver operating characteristic (ROC) curve analysis.
Results: The results indicated that IL-37 serum concentrations were markedly higher in patients than in the control group, although no association with the patients' clinicopathological characteristics was found. The best cut-off point for the serum IL-37 level was 61.95 pg/ml, with a sensitivity of 92.30% and specificity of 87.70%. The ROC curve area was 0.90.
Conclusion: The significant increase of serum IL-37 levels in oral SCC patients underscores its involvement in the disease's pathology and suggests its potential use in early detection and screening. Future studies should aim to elucidate the interplay of this cytokine with the tumor microenvironment (TME) and explore its possible diagnostic and therapeutic applications in cancer.

Keywords

Oral Squamous Cell Carcinoma

Interleukin 37 Protein

Enzyme-Linked Immunosorbent Assay

Kim YJ, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020; 10: 7877.
Ghaderi H, Kruger E, Ahmadvand S, Mohammadi Y, Khademi B, Ghaderi A. Epidemiological profile of salivary gland tumors in southern Iranian population: A retrospective study of 405 cases. J Cancer Epidemiol. 2023; 2023: 8844535.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6:92.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Radiation Therapy Oncology Group 9501/ Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019; 19: 105-119.
Ghaderi H, Roshan-Zamir M, Jafarinia M, Kruger E. Oral Squamous Cell Carcinoma: Focus on Biomarkers for Screening. J Dent (Shiraz). 2024; 25: 1-16.
Tuong ZK, Lewandowski A, Bridge JA, Cruz JLG, Yamada M, Lambie D, et al. Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. Sci Rep. 2019; 9: 17754.
Sun Y, Liu N, Guan X, Wu H, Sun Z, Zeng H. Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma. Mediators Inflamm. 2016; 2016: 5715719.
Mirjalili N, Kheirollahi K. Correlation between chronic inflammation and oral squamous cell carcinoma (OSCC). Oral Oncol. 2014; 50: e52.
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117: 1175-1183.
Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006; 4: 48.
Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006; 25: 409-416.
Gu M, Jin Y, Gao X, Xia W, Xu T, Pan S. Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front Immunol. 2023; 14: 1278521.
Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-37 in cancer. Med Oncol. 2016; 33: 68.
Wu BW, Zeng QT, Meng K, Ji QW. The potential role of IL-37 in atherosclerosis. Pharmazie. 2013; 68: 857-860.
Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 2012; 27: 1609-1616.
Li Y, Wang Z, Yu T, Chen B, Zhang J, Huang K, et al. Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS One. 2014; 9: e107183.
Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014; 2014: 165742.
Zhu Y, Qin H, Ye K, Sun C, Qin Y, Li G, et al. Dual role of IL-37 in the progression of tumors. Cytokine. 2022; 150: 155760.
Wang S, An W, Yao Y, Chen R, Zheng X, Yang W, et al. Interleukin 37 Expression Inhibits STAT3 to Suppress the Proliferation and Invasion of Human Cervical Cancer Cells. J Cancer. 2015; 6: 962-969.
Ge G, Wang A, Yang J, Chen Y, Yang J, Li Y, Xue Y. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2016; 35: 13.
Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression. Oncotarget. 2017; 8: 49064-49075.
Lin L, Wang J, Liu D, Liu S, Xu H, Ji N, et al. Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma. Sci Rep. 2016; 6: 26757.
Yotsukura S, Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 2015; 93: 103-115.
Mohammed A, Biegert G, Adamec J, Helikar T. Identification of potential tissue-specific cancer biomarkers and development of cancer versus normal genomic classifiers. Oncotarget. 2017; 8: 85692-85715.
Ding L, Zhao X, Zhu N, Zhao M, Hu Q, Ni Y. The balance of serum IL-18/IL-37 levels is disrupted during the development of oral squamous cell carcinoma. Surg Oncol. 2020; 32: 99-107.
Jiang Y, Wang Y, Liang L, Gao Y, Chen J, Sun Y, et al. IL-37 mediates the antitumor activity in renal cell carcinoma. Med Oncol. 2015; 32: 250.
Li ZC, Sun MD, Zheng YQ, Fu HJ. The Low Expression of IL-37 Involved in Multiple Myeloma- Associated Angiogenesis. Med Sci Monit. 2016; 22: 4164-4168.
Li P, Guo H, Wu K, Su L, Huang K, Lai R, et al. Decreased IL-37 expression in hepatocellular carcinoma tissues and liver cancer cell lines. Oncol Lett. 2020; 19: 2639-2648.
Dang J, He Z, Cui X, Fan J, Hambly DJ, Hambly BD, et al. The Role of IL-37 and IL-38 in Colorectal Cancer. Front Med (Lausanne). 2022; 9: 811025.
Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Arch Gynecol Obstet. 2017; 295: 459-465.
Zhang Y, Tang M, Wang XG, Gu JH, Zhou LN, Jin J, et al. Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer. Rev Esp Enferm Dig. 2019; 111: 941-945.
Haghshenas MR, Hosseini SR, Fattahi MJ, Malekzadeh M, Ariafar A, Ghaderi A. Elevated IL-37 Serum Levels in Patients with Transitional Cell Carcinoma of Bladder. Iran J Immunol. 2021; 18: 346-353.
Haghshenas MR, Saffarian A, Khademolhosseini A, Dehghanian A, Ghaderi A, Sotoodeh Jahromi A. Simultaneous Increase in Serum Levels of IL-37 and IL-18 Binding Protein In Low-Grade and High-Grade Brain Tumors. Asian Pac J Cancer Prev. 2022; 23: 2851-2856.
Haghshenas MR, Shiravani Z, Samare-Najaf M, Khansalar S, Razavinasab SA, Ghaderi A, et al. Clinical significance of IL-37 serum level and polymorphism in patients with endometrial cancer. Eur Cytokine Netw. 2023; 34: 63-69.
Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep. 2014; 4: 5177.
Christodoulou P, Kyriakou TC, Boutsikos P, Andreou M, Ji Y, Xu D, et al. Aberrant Expression and Prognostic Potential of IL-37 in Human Lung Adenocarcinoma. Biomedicines. 2022; 10: 3037.